Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study
Nightingale Health will run the measurements in its labs using Alamar’s NULISA platform to quantify hundreds of blood proteins in 80,000 UK Biobank samples, seeking early molecular signs of neurodegeneration.